adenoviral Flt3L

Adenoviral Flt3L (Ad-Flt3L) is an investigational gene therapy biologic consisting of a recombinant adenoviral vector engineered to express the human Fms-like tyrosine kinase 3 ligand (Flt3L) transgene. Flt3L is a potent hematopoietic growth factor that stimulates the recruitment, proliferation, and activation of dendritic cells (DCs) and natural killer (NK) cells. By delivering the Flt3L gene directly into the tumor microenvironment, the therapy aims to increase the local density of professional antigen-presenting cells, thereby enhancing the priming of T-cell-mediated anti-tumor immunity. It has been primarily studied for the treatment of high-grade gliomas, often administered in a dual-vector approach alongside a second adenoviral vector expressing herpes simplex virus type 1 thymidine kinase (Ad-TK) to induce immunogenic cell death. Clinical development has been primarily led by academic researchers at the University of Michigan.

Other names

adenoviral Fms-like tyrosine kinase 3 ligand